Atlas Private Wealth Management’s TherapeuticsMD TXMD Stock Holding History

Atlas Private Wealth Management’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-13	Closed	-$1K	–	348
2021 Q1	$1K	Hold	13	–	–	﹤0.01%	392
2020 Q4	$1K	Hold	13	–	–	﹤0.01%	361
2020 Q3	$1K	Hold	13	–	–	﹤0.01%	382
2020 Q2	$1K	Hold	13	–	–	﹤0.01%	446
2020 Q1	$1K	Hold	13	–	–	﹤0.01%	439
2019 Q4	$2K	Buy	+13	New	+$1.87K	﹤0.01%	438

Other funds holding TXMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Atlas Private Wealth Management's TXMD Position: Q2 2021 in Review

Atlas Private Wealth Management sold out of TherapeuticsMD (TXMD) in Q2 2021, closing a stake of 13 shares — an estimated $1K sold.

Atlas Private Wealth Management first reported a position in TXMD in Q4 2019 and held it in 6 quarters. The position peaked at $2K in Q4 2019. 154 funds tracked by Wall St. Rank hold TXMD as of Q2 2021.

Atlas Private Wealth Management reported no remaining TherapeuticsMD position as of Q2 2021 after selling out during the quarter.
Atlas Private Wealth Management sold 13 TherapeuticsMD shares in Q2 2021, an estimated $1K.
Atlas Private Wealth Management first reported a position in TherapeuticsMD in Q4 2019 and held it in 6 quarters.
Atlas Private Wealth Management's TherapeuticsMD position peaked at $2K in Q4 2019.
154 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2021.

Based on Atlas Private Wealth Management's 13F filing for Q2 2021, filed 5 Aug 2021.